TABLE 1.
Baseline Characteristics of the Study Population at Waitlist Registration
| Characteristics | Status 1a (n = 3,377) | ACLF-3 (n = 5,099) | P |
|---|---|---|---|
| Age, mean (SD) | 42.9 (14.5) | 51.8 (10.6) | <0.001 |
| Male, n (%) | 1,273 (37.8) | 3,149 (61.6) | <0.001 |
| Race, n (%) | <0.001 | ||
| Caucasian | 2,154 (63.7) | 3,289 (64.5) | 0.499 |
| African American | 547 (16.2) | 646 (12.7) | |
| Hispanic | 375 (11.1) | 827 (16.2) | |
| Acetaminophen toxicity | 664 (19.8) | ||
| Etiology of cirrhosis, n (%) | |||
| NASH | 690 (13.5) | ||
| HCV | 1,734 (34.0) | ||
| ALD | 1,189 (23.3) | ||
| Other | 1,486 (29.1) | ||
| Body mass index, median (IQR) | 26.9 (23.3–31.5) | 28.5 (24.7–33.2) | 0.002 |
| Diabetes mellitus, n (%) | 346 (10.6) | 1,113 (22.6) | <0.001 |
| Albumin, median (IQR) | 2.8 (2.4–3.2) | 3 (2.5–3.5) | 0.001 |
| Portal vein thrombosis, n(%) | 133 (4.2) | 282 (5.9) | 0.001 |
| MELD score, median (IQR) | 34.5 (28.8–40.8) | 39.3 (34.4–43.6) | |
| MELD-Na score, median (IQR) | 34.7 (28.9–40.9) | 39.2 (34.9–42.9) | <0.001 |
| Total bilirubin, median (IQR) | 8.9 (4.2–20.9) | 22.7 (13.7–33.3) | <0.001 |
| Creatinine, median (IQR) | 1.6 (1–3.4) | 3.7 (2.1–4) | <0.001 |
| INR, median (IQR) | 3.3 (2.3–5.1) | 2.7 (2.0–3.3) | <0.001 |
| Organ failure | |||
| Liver failure, n (%) | 1,429 (42.4) | 4,110 (80.7) | <0.001 |
| Mechanical ventilation, n (%) | 1,715 (50.8) | 2,157 (42.3) | <0.001 |
| Circulatory failure, n (%) | 1,757 (52.2) | 2,372 (46.5) | <0.001 |
| Coagulation failure, n (%) | 2,396 (70.9) | 3,212 (62.9) | <0.001 |
| Neurologic failure, n (%) | 1,928 (57.1) | 2,694 (52.8) | <0.001 |
| Renal failure, n (%) | 1,438 (42.6) | 4,078 (79.8) | <0.001 |
| Hemodialysis, n (%) | 498 (14.8) | 1,906 (37.6) | <0.001 |
| Number of organ failures | |||
| Four | 1,393 (41.3) | 1,648 (32.3) | <0.001 |
| Five | 637 (18.9) | 685 (12.4) | 0.002 |
| Six | 137 (4.1) | 225 (4.4) | 0.424 |
Abbreviation: IQR, interquartile range.